5 research outputs found
Spread of a SARS-CoV-2 variant through Europe in the summer of 2020.
Following its emergence in late 2019, the spread of SARS-CoV-21,2 has been tracked by phylogenetic analysis of viral genome sequences in unprecedented detail3–5. Although the virus spread globally in early 2020 before borders closed, intercontinental travel has since been greatly reduced. However, travel within Europe resumed in the summer of 2020. Here we report on a SARS-CoV-2 variant, 20E (EU1), that was identified in Spain in early summer 2020 and subsequently spread across Europe. We find no evidence that this variant has increased transmissibility, but instead demonstrate how rising incidence in Spain, resumption of travel, and lack of effective screening and containment may explain the variant’s success. Despite travel restrictions, we estimate that 20E (EU1) was introduced hundreds of times to European countries by summertime travellers, which is likely to have undermined local efforts to minimize infection with SARS-CoV-2. Our results illustrate how a variant can rapidly become dominant even in the absence of a substantial transmission advantage in favourable epidemiological settings. Genomic surveillance is critical for understanding how travel can affect transmission of SARS-CoV-2, and thus for informing future containment strategies as travel resumes. © 2021, The Author(s), under exclusive licence to Springer Nature Limited
EFFICACY AND SAFETY OF SEBELIPASE ALFA IN CHILDREN AND ADULTS WITH LYSOSOMAL ACID LIPASE DEFICIENCY: RESULTS OF A PHASE 3 TRIAL
50th International Liver Congress of the European-Association-for-the-Study-of-the-Liver -- APR 22-26, 2015 -- Vienna, AUSTRIAWOS: 000362830900402European Assoc Study Live
A phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency
Background: Lysosomal acid lipase is an essential lipid-metabolizing enzyme that breaks down endocytosed lipid particles and regulates lipid metabolism. We conducted a phase 3 trial of enzyme-replacement therapy in children and adults with lysosomal acid lipase deficiency, an underappreciated cause of cirrhosis and severe dyslipidemia. Methods: In this multicenter, randomized, double-blind, placebo-controlled study involving 66 patients, we evaluated the safety and effectiveness of enzyme-replacement therapy with sebelipase alfa (administered intravenously at a dose of 1 mg per kilogram of body weight every other week); the placebo-controlled phase of the study was 20 weeks long and was followed by open-label treatment for all patients. The primary end point was normalization of the alanine aminotransferase level. Secondary end points included additional disease-related efficacy assessments, safety, and side-effect profile. Results: Substantial disease burden at baseline included a very high level of low-density lipoprotein cholesterol (≥190 mg per deciliter) in 38 of 66 patients (58%) and cirrhosis in 10 of 32 patients (31%) who underwent biopsy. A total of 65 of the 66 patients who underwent randomization completed the double-blind portion of the trial and continued with open-label treatment. At 20 weeks, the alanine aminotransferase level was normal in 11 of 36 patients (31%) in the sebelipase alfa group and in 2 of 30 (7%) in the placebo group (P = 0.03), with mean changes from baseline of -58 U per liter versus -7 U per liter (P<0.001). With respect to prespecified key secondary efficacy end points, we observed improvements in lipid levels and reduction in hepatic fat content (P<0.001 for all comparisons, except P = 0.04 for triglycerides). The number of patients with adverse events was similar in the two groups; most events were mild and were considered by the investigator to be unrelated to treatment. Conclusions: Sebelipase alfa therapy resulted in a reduction in multiple disease-related hepatic and lipid abnormalities in children and adults with lysosomal acid lipase deficiency. (Funded by Synageva BioPharma and others; ARISE ClinicalTrials.gov number, NCT01757184.
A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency
BACKGROUND
Lysosomal acid lipase is an essential lipid-metabolizing enzyme that
breaks down endocytosed lipid particles and regulates lipid metabolism.
We conducted a phase 3 trial of enzyme-replacement therapy in children
and adults with lysosomal acid lipase deficiency, an underappreciated
cause of cirrhosis and severe dyslipidemia.
METHODS
In this multicenter, randomized, double-blind, placebo-controlled study
involving 66 patients, we evaluated the safety and effectiveness of
enzyme-replacement therapy with sebelipase alfa (administered
intravenously at a dose of 1 mg per kilogram of body weight every other
week); the placebo-controlled phase of the study was 20 weeks long and
was followed by open-label treatment for all patients. The primary end
point was normalization of the alanine aminotransferase level. Secondary
end points included additional disease-related efficacy assessments,
safety, and side-effect profile.
RESULTS
Substantial disease burden at baseline included a very high level of
low-density lipoprotein cholesterol (>= 190 mg per deciliter) in 38 of
66 patients (58\%) and cirrhosis in 10 of 32 patients (31\%) who
underwent biopsy. A total of 65 of the 66 patients who underwent
randomization completed the double-blind portion of the trial and
continued with open-label treatment. At 20 weeks, the alanine
aminotransferase level was normal in 11 of 36 patients (31\%) in the
sebelipase alfa group and in 2 of 30 (7\%) in the placebo group (P =
0.03), with mean changes from baseline of -58 U per liter versus -7 U
per liter (P<0.001). With respect to pre-specified key secondary
efficacy end points, we observed improvements in lipid levels and
reduction in hepatic fat content (P<0.001 for all comparisons, except P
= 0.04 for triglycerides). The number of patients with adverse events
was similar in the two groups; most events were mild and were considered
by the investigator to be unrelated to treatment.
CONCLUSIONS
Sebelipase alfa therapy resulted in a reduction in multiple
disease-related hepatic and lipid abnormalities in children and adults
with lysosomal acid lipase deficiency. (Funded by Synageva BioPharma and
others; ARISE ClinicalTrials.gov number, NCT01757184.